(Q41728099)

8 October 2017

Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. (English)

1 reference

8 October 2017

17

1 reference

8 October 2017

Tariq Ahmad

1

1 reference

8 October 2017

Philip Yin

2

1 reference

8 October 2017

Jeffrey Saffitz

3

1 reference

8 October 2017

Paul J Pockros

4

1 reference

8 October 2017

Jacob Lalezari

5

1 reference

8 October 2017

Mitchell Shiffman

6

1 reference

8 October 2017

Bradley Freilich

7

1 reference

8 October 2017

Joann Zamparo

8

1 reference

8 October 2017

Kyle Brown

9

1 reference

8 October 2017

Dessislava Dimitrova

10

1 reference

8 October 2017

Monica Kumar

11

1 reference

8 October 2017

Doug Manion

12

1 reference

8 October 2017

Margo Heath-Chiozzi

13

1 reference

8 October 2017

Robert Wolf

14

1 reference

8 October 2017

Eric Hughes

15

1 reference

8 October 2017

Andrew J Muir

16

1 reference

8 October 2017

language of work or name

English

0 references

publication date

24 September 2014

1 reference

8 October 2017

1 reference

8 October 2017

62

1 reference

8 October 2017

409-416

1 reference

8 October 2017

2

1 reference

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

8 October 2017

1 reference

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

Current and future therapies for hepatitis C virus infection

21 January 2018

1 reference

The race for interferon-free HCV therapies: a snapshot by the spring of 2012.

21 January 2018

1 reference

Expediting drug development--the FDA's new "breakthrough therapy" designation

21 January 2018

1 reference

INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.

21 January 2018

1 reference

A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2061.

21 January 2018

1 reference

Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.

21 January 2018

1 reference

The FDA critical path initiative and its influence on new drug development.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HEP.27488

1 reference

8 October 2017

1 reference